Affimed (AFMD)

• Market cap: $19.5M
• 1 day: 0.85%
• 5 days: -44.65%
• 1 month: -56.25%
• 3 months: -67.75%
• 6 months: -79.83%
• Year to date: -80.96%
• 1 year: -68.52%
• 5 years: -95.67%
• 10 years: -98.13%

About: Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Employees: 78

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

5% less call options, than puts

Call options by funds: $39K | Put options by funds: $41K

1.48% less ownership

Funds ownership: 21.5% [Q2] → 20.02% (-1.48%) [Q3]

12% less funds holding

Funds holding: 43 [Q2] → 38 (-5) [Q3]

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

43% less capital invested

Capital invested by funds: $17.8M [Q2] → $10.2M (-$7.57M) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 236% upside
• Avg. target: $9.67 712% upside
• High target: $15 1,161% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Wells Fargo Yanan Zhu 6% 1-year accuracy 1 / 17 met price target	1,161% upside $15	Overweight Maintained	12 Dec 2024
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target	740% upside $10	Buy Reiterated	10 Dec 2024
Stifel Bradley Canino 21% 1-year accuracy 7 / 33 met price target	236% upside $4	Hold Maintained	15 Nov 2024